This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
by Zacks Equity Research
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
by Urmimala Biswas
Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?
Why Is Techne (TECH) Down 3% Since Last Earnings Report?
by Zacks Equity Research
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
by Sundeep Ganoria
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $71.93, moving -1.24% from the previous trading session.
Danaher Partners With AstraZeneca to Support Precision Medicine
by Zacks Equity Research
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
by Kinjel Shah
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy?
by Urmimala Biswas
BFLY outpaces TEM with stronger upside, leaner valuation, and expanding global reach in AI-powered diagnostics.
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
by Zacks Equity Research
RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust
by Zacks Equity Research
Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust are part of the Zacks top Analyst Blog.
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
Top Research Reports for Visa, AstraZeneca & Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and Shell plc (SHEL), as well as two micro-cap stocks Ocean Power Technologies, Inc. (OPTT) and Wheeler Real Estate Investment Trust, Inc. (WHLR).
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
by Zacks Equity Research
The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study
by Zacks Equity Research
Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?
by Urmimala Biswas
President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales
by Zacks Equity Research
BAYRY's first-quarter earnings beat expectations. Revenues miss estimates, mainly due to lower sales of its products in the Crop Science division.
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
by Zacks Equity Research
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.